Andreas Schneeweiss

发表

Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade.

Jane E. Carpenter, Kyriaki Michailidou, France Labrèche, 2014, Human molecular genetics.

Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast

Julian Peto, Matthias W. Beckmann, Peter A. Fasching, 2014, PLoS genetics.

Abstract PD1-02: Cancer predisposition genes in metastatic breast cancer – Association with metastatic pattern, prognosis, patient and tumor characteristics

Steven N. Hart, Chunling Hu, Peter A. Fasching, 2018 .

Identification of Novel Genetic Markers of Breast Cancer Survival

Peter Kraft, Nazneen Rahman, Janet A. Dunn, 2015, Journal of the National Cancer Institute.

Circulating microRNAs in plasma as early detection markers for breast cancer

Axel Benner, Barbara Burwinkel, Manuela Zucknick, 2013, International journal of cancer.

19p13.1 is a triple-negative-specific breast cancer susceptibility locus.

Daniel J. Park, Julian Peto, Kamila Czene, 2012, Cancer research.

CD24 polymorphisms in breast cancer: impact on prognosis and risk

Barbara Burwinkel, Petra Seibold, Andreas Schneeweiss, 2013, Breast Cancer Research and Treatment.

Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer.

Roland Eils, Axel Benner, Benedikt Brors, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

Wei Lu, Wei Zheng, Mads Thomassen, 2013, Nature Genetics.

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

Carsten Denkert, Peter A Fasching, Andreas Schneeweiss, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Arlene Chan, Andreas Schneeweiss, Luc Y Dirix, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay

Tim Holland-Letz, Andreas Trumpp, Tobias Bäuerle, 2013, Nature Biotechnology.

Circulating miRNAs as Surrogate Markers for Circulating Tumor Cells and Prognostic Markers in Metastatic Breast Cancer

Axel Benner, Andreas Trumpp, Barbara Burwinkel, 2012, Clinical Cancer Research.

Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: The SUCCESS trial.

Brigitte Rack, Matthias W. Beckmann, Andreas Schneeweiss, 2010 .

Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)

Patrick Neven, Hui Zhao, Nazneen Rahman, 2012, PloS one.

Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium.

Patrick Neven, Päivi Heikkilä, Giu-Cheng Hsu, 2011, Human molecular genetics.

Plasma MicroRNA Panel for Minimally Invasive Detection of Breast Cancer

Michael Golatta, Barbara Burwinkel, Manuela Zucknick, 2013, PloS one.

Targeted next‐generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance

Jan Budczies, Nicole Pfarr, Volker Endris, 2017, Genes, chromosomes & cancer.

Intrinsic breast cancer subtypes defined by estrogen receptor signalling—prognostic relevance of progesterone receptor loss

Petra Seibold, Andreas Schneeweiss, Jenny Chang-Claude, 2013, Modern Pathology.

Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium.

Michael Jones, Nazneen Rahman, Michael Bremer, 2011, Human molecular genetics.

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial

Peter A. Fasching, Carsten Denkert, Andreas Schneeweiss, 2018, BMC Medicine.

Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis.

Andreas Trumpp, Barbara Burwinkel, Manuela Zucknick, 2016, Carcinogenesis.

Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences

Carsten Denkert, Jan Budczies, Nicole Pfarr, 2014, Oncotarget.

Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers.

Wei Lu, Päivi Heikkilä, Peter Kraft, 2013, American journal of human genetics.

Genome-wide association studies identify four ER negative–specific breast cancer risk loci

Patrick Neven, Michael Jones, Wei Lu, 2013, Nature Genetics.

Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study

Patrick Neven, Chiun-Sheng Huang, Julian Peto, 2014, Breast Cancer Research.

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

Andreas Schneeweiss, Nadia Harbeck, Christoph Thomssen, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response-guided neoadjuvant chemotherapy for breast cancer.

Carsten Denkert, Andreas Schneeweiss, Stefan Paepke, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prediction of local recurrence risk after neoadjuvant chemotherapy in patients with primary breast cancer: Clinical utility of the MD Anderson Prognostic Index

Michael Golatta, Andreas Schneeweiss, André Hennigs, 2019, PloS one.

Reverse phase protein array based tumor profiling identifies a biomarker signature for risk classification of hormone receptor-positive breast cancer

Rainer König, Tim Beißbarth, Stefan Wiemann, 2014 .

11q13 is a susceptibility locus for hormone receptor positive breast cancer

Patrick Neven, Michael Jones, Michael Bremer, 2012, Human mutation.

Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients

Tanja Fehm, Brigitte Rack, Matthias W. Beckmann, 2014, Journal of the National Cancer Institute.

Pairwise relationships between relative mRNA expression levels of ERR α and selected receptors , cofactors , and target genes in breast cancer tissues ( tumor set I , n = 48 )

Andreas Schneeweiss, Peter Lichter, Christof Sohn, 2009 .

Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/ cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase II trial.

Andreas Schneeweiss, Peter Lichter, Christof Sohn, 2007, Clinical breast cancer.

Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1.

Wei Lu, Nina Ditsch, Julian Peto, 2013, American journal of human genetics.

Genome-wide association analysis identifies three new breast cancer susceptibility loci

Michael Jones, Nazneen Rahman, Daniel J. Park, 2012, Nature Genetics.

Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients

Andreas Trumpp, Barbara Burwinkel, Andreas Schneeweiss, 2014, BMC Cancer.